Plain-English translation of NCT06189157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of cell therapy designed to help people with severe lupus whose disease has not responded to standard treatments. The treatment works by using specially engineered immune cells to help control the disease. Researchers will start with small doses and gradually increase them to find the safest and most effective dose.
Current lupus medications don't work well enough for everyone, and some people's disease continues to cause serious damage to organs like the kidneys, heart, and lungs despite trying multiple treatments. This trial is exploring whether this new cell-based approach might help patients whose lupus has been difficult to control.
You likely qualify if…
You likely don't qualify if…
You will receive one dose of the medication through an infusion. For the first month after treatment, you'll have frequent visits to the hospital or clinic for blood tests and vital sign checks to monitor for side effects. Then you'll continue to be monitored at less frequent intervals for a full year, with blood draws to see how the cells are behaving and whether your lupus is improving. After that, you'll be followed annually for up to 15 years total to track long-term safety and how well the treatment works over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Germany